ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse

ATAI Life Sciences AG, a global biotechnology company builder that envisions an end to mental illnesses, has acquired a majority stake in New York-based pharmaceutical company Kures, which targets the important intersection between pain and opioid use disorder. Additionally, Srinivas Rao, MD, PhD, Chief Scientific Officer of ATAI Life Sciences, has been appointed CEO of Kures.